# ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

> **NCT05446298** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **OncoC4, Inc.** · enrollment: 58 (actual)

## Conditions studied

- Ovarian Cancer
- High Grade Serous Adenocarcinoma of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer

## Interventions

- **DRUG:** ONC-392
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05446298
- **Lead sponsor:** OncoC4, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-22
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05446298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05446298, "ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05446298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*